Senior Analyst Glenn Novarro of RBC Capital Markets foresees Johnson & Johnson (JNJ) experiencing strong pharmaceutical growth and a recovery of consumer sales growth in 2014, followed by outperformance in operating margins in 2015.
“We think Johnson & Johnson has the fastest-growing pharmaceutical business in the world in terms of revenue growth over the next few years. They’re bringing more new products to the market than any pharmaceutical company, and they don’t have any major patent issues in the near term,” Novarro said.
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Johnson & Johnson is also focused on its consumer business, bringing back products such as Children’s Tylenol and Children’s Motrin, Novarro says. He expects the product spend to slow after this year, resulting in an outperformance in operating margins.
“We think there is a better chance for a significant gain in 2015. We think that some of the spend behind the new pharmaceutical products and the consumer re-launches will start to slow, and that’s going to drive a significant outperformance in operating margins in 2015.” Novarro said.
Johnson & Johnson (JNJ) a High-Dividend, Value-Like Stock
February 02, 2016
Continued Stability for Johnson & Johnson (NYSE:JNJ)
November 30, 2016
Hospira (HSP) to Overcome FDA Setbacks and See Recovery
March 08, 2013